Clinical Trial Detail

NCT ID NCT01774786
Title A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Pertuzumab

Capecitabine + Cisplatin + Fluorouracil + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST